Tim Gallagher, RPh
Executive Vice President of Pharmacy Operations Astrup Drug, Inc.
Tim Gallagher, RPh, is the Executive Vice President of Pharmacy Operations at Astrup Drug, Inc. Minnesota. He manages all aspects of pharmacy operations for the company. Mr. Gallagher has been a practicing pharmacist for 23 years in both the chain and independent community pharmacy setting. He has also been a consultant pharmacist in the long-term care industry. Mr. Gallagher is active in several professional pharmacy organizations at both the state and national level. He is a member of the Board of Directors and Past President of the Minnesota Pharmacists Association, where he chaired the Public Affairs Committee, which develops and implements polices for the Association and oversees all legislative activities. Mr. Gallagher also sits on the Medicaid Payment Reform Advisory Committee for the Minnesota Department of Human Services. His primary area of interest is in psychopharmacology. (This is me - Update Profile)
| 1999 - present | Executive Vice President of Pharmacy Operations Astrup Drug, Inc. |
|---|---|
| 1994 - 1999 | Pharmacy Manager Sterling Drug |
GLG Study Groups with Tim Gallagher, RPh(?)
| Study Group Name | Members |
|---|---|
| Generic Drug Economic Experts | 596 |
| Pharmacists (US) | 2074 |
| Physicians who Treat Onychomycosis (US) | 95 |
| Economic Experts on Managed Care | 607 |
GLG NewsSM
Analyses by Tim Gallagher, RPh(?)
An FDA advisory panel recently voted to stop the recommendation of otc cough and cold products in children less than 12 years of age. For decades parents have administered otc cough and could products to infants and young children. Even the FDA Advisory Committee had dissention amongst their members,...
Pfizer failed miserably in its attempt to provide diabetic patients with an easy-to-use inhaled insulin as an alternative to injectable insulin. A product they projected would generate sales of $2 billion a year recorded a disappointing $12 million in sales this year. CEO Kindler said he decided to...
The FDA recently approved a 250mg Soma® tablet manufactured by MedPointe Pharmaceuticals as a new recommended dose for the treatment of painful musculoskeletal problems such as backache. The drug is not new, in fact it has been around for nearly 50 years, first receiving FDA approval...
The FDA recently approved the expanded use of FluMist, the only nasal spray influenza vaccine, in children 2 to 5 years of age. Each year in the U.S up to 60 million Americans get the flu according to the CDC. The U.S. CDC recommends all children aged 6 to 59 months be vaccinated against the flu. FluMist...
GLG InstituteSM Seminars with Tim Gallagher, RPh(?)
View all GLG InstituteSM Seminars in Healthcare
Request a project with Tim Gallagher, RPh
Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms